Vavricka John 4

4 · Atea Pharmaceuticals, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Atea (AVIR) CCO John Vavricka Receives RSU Award, Exercises Derivatives

What Happened

John Vavricka, Chief Commercial Officer of Atea Pharmaceuticals (AVIR), received a grant of 119,520 restricted stock units (RSUs) and had derivative instruments converted/exercised on January 31, 2026. The filing shows 42,083 shares acquired via exercise/conversion and 53,653 shares disposed (11,570 withheld to cover taxes valued at $49,057; plus 33,333 and 8,750 shares reported as derivative dispositions at $0). Net effect in this report: an increase of 107,950 shares (161,603 acquired less 53,653 surrendered/withheld).

Key Details

Transaction date: January 31, 2026; Form 4 filed February 3, 2026 (file appears timely).
Tax withholding: 11,570 shares withheld at $4.24/share for $49,057 (code F).
Acquisitions: 119,520 RSUs (code A) and 42,083 shares from exercise/conversion of derivatives (code M). Several derivative conversions/dispositions are shown at $0 (codes M).
Net share change reported here: +107,950 shares (161,603 acquired – 53,653 disposed/withheld).
Shares owned after transaction: not provided in the excerpt supplied.
Footnotes: RSUs convert to one share each (F1). A prior 100,000 RSU grant fully vested as of 1/31/2026 (F2). Performance RSUs vested on 1/31/2026 (F3). A separate option grant vests monthly beginning after 1/31/2026 and fully vests 1/31/2030 (F4).

Context

The report combines awards/vestings (RSUs) and derivative conversions/exercises—common for executives upon vesting. The tax withholding (F) shows shares surrendered to cover tax obligations; derivative dispositions at $0 often reflect net settlement mechanics rather than market sales. These filings are factual disclosures of compensation-related stock events and do not by themselves indicate insider market sentiment.

Form 4

Period: 2026-01-31

Chief Commercial Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-31+42,083→ 94,164 total
Tax Payment
Common Stock
2026-01-31$4.24/sh−11,570$49,057→ 82,594 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-01-31−33,333→ 0 total
→ Common Stock (33,333 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F3]
2026-01-31−8,750→ 0 total
→ Common Stock (8,750 underlying)
Award
Stock Option (Right to Buy)
[F4]
2026-01-31+119,520→ 119,520 total
Exercise: $4.24Exp: 2036-01-30→ Common Stock (119,520 underlying)

Holdings

Footnotes (4)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
[F2]The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
[F3]Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
[F4]The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.

Signature

/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka|2026-02-03

1 file